NOR-SWITCH Results ‘Concerning’ In Crohn’s Disease, Says Janssen

Janssen Biotech says that the NOR-SWITCH study on switching from Remicade to biosimilar infliximab raises “significant questions” over safety and efficacy in patients with Crohn’s disease, and does not support interchangeability.

Paths
How far should biosimilars be interchangeable?

The results of NOR-SWITCH, the Norwegian government-sponsored study on switching patients from Johnson & Johnson’s Remicade (infliximab) to Celltrion’s biosimilar version Remsima (CT-P13), have generated a great deal of controversy since they were published last month, especially over how far the data support the safety of switching.

Now J&J subsidiary Janssen Biotech Inc., which has been advocating clinical testing of biosimilars across the different indications of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics